APEX is a pharmaceutical company leveraging psychedelic compounds to develop data-backed, clinically evaluated pharmaceuticals for depression in Veterans with PTSD. The company has multiple drug candidates in the pipeline, including a low-dose synthetic psilocybin-derived treatment, APEX-002-A01. The drug is being developed through a promising strategic, staged clinical program aimed at receiving Health Canada approval. We are facing a mental health crisis for Veterans, with high suicide rates, and a lack of a true standard of mental health care for these communities. APEX is driven by an experienced and passionate leadership team from the Veteran community, healthcare, drug policy and emerging sectors who want to make a difference and disrupt the $380+ billion global mental health market. APEX has built a network of Veterans, practitioners, and stakeholders, and are advocating to expand access to the care patients need via early medical access programs and a robust clinical trial pipeline. What’s more, the company is laying the infrastructure to use even more New Chemical Entities (NCEs) to develop innovative pharmaceuticals targeted at a broad range of mental health conditions. Find out more at apexlabs.com